BMT is an effective therapy for many otherwise lethal diseases including leukemia. 1 GVHD is one of the most critical complications accompanying BMT. [2][3][4] To reduce the incidence of GVHD, a number of methods have been established in murine and human systems. 4-11 Elimination of mature T cells from donor BM cells (BMC) is one of the most reliable methods. However, the complete elimination of allogeneic T cells has been shown to increase the frequency of failure of allogeneic engraftment. [12][13][14][15][16][17] In addition, it has been reported that GVHD has beneficial effects in preventing recurrence of leukemia via the GVL response. 18 We have reported that BMT mice prepared by inoculation of a small number of T cells with BMC from both MHC class I and non-MHC Ag disparate mice show signs of clinical GVHD at an early stage after BMT. 19 The acute GVHD resulted in abrogation of the thymic negative selection of the self-reactive T cell repertoire. 11,20 In the present study, using the same experimental BMT system we investigated functions and TCR V repertoires of T cells in the bone marrow chimeras which had recovered from the acute GVHD that had been induced by mismatches at the H-2D and non-MHC loci including minor lymphocyte stimulatory (Mls)-1 locus. The Mls-1 a Ag is an endogenous superantigen and stimulates several repertories of T cells in the absence of priming. 21,22 We report here a split tolerance of T cells induced in these chimeras. These T cells showed a significant proliferative response but no CTL activity to the recipient cells. To elucidate the mechanism(s) underlying the split tolerance, we analyzed the pattern of cytokine production by these T cells.